Cargando…

Abaloparatide for risk reduction of nonvertebral and vertebral fractures in postmenopausal women with osteoporosis: a network meta-analysis

SUMMARY: This network meta-analysis assessed the efficacy of abaloparatide versus other treatment options to reduce the risk of fractures in women with postmenopausal osteoporosis. The analysis indicates that abaloparatide reduces the risk of fractures in women with postmenopausal osteoporosis versu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reginster, J. -Y., Bianic, F., Campbell, R., Martin, M., Williams, S. A., Fitzpatrick, L. A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer London 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6614166/ https://www.ncbi.nlm.nih.gov/pubmed/30953114 http://dx.doi.org/10.1007/s00198-019-04947-2

Ejemplares similares

Effect of abaloparatide on vertebral, nonvertebral, major osteoporotic, and clinical fractures in a subset of postmenopausal women at increased risk of fracture by FRAX probability
por: McCloskey, E. V., et al.
Publicado: (2019)

Geography of Fracture Incidence in Postmenopausal Women with Osteoporosis Treated with Abaloparatide
por: McClung, Michael R., et al.
Publicado: (2017)

Correction to: Geography of Fracture Incidence in Postmenopausal Women with Osteoporosis Treated with Abaloparatide
por: McClung, Michael R., et al.
Publicado: (2018)

Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis
por: Leder, Benjamin Z, et al.
Publicado: (2019)

ERRATUM for “Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis”
Publicado: (2020)

Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis
por: Watts, N.B., et al.
Publicado: (2019)

Abaloparatide is an Effective Treatment Option for Postmenopausal Osteoporosis: Review of the Number Needed to Treat Compared with Teriparatide
por: Reginster, Jean-Yves, et al.
Publicado: (2018)

Correction to: Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis
por: Watts, N. B., et al.
Publicado: (2020)

Correction to: Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis
por: Watts, N. B., et al.
Publicado: (2020)

Profile of Abaloparatide and Its Potential in the Treatment of Postmenopausal Osteoporosis
por: Tella, Sri Harsha, et al.
Publicado: (2017)

OR03-1 The Effect of Abaloparatide on Bone Mineral Density and Fracture Incidence in Postmenopausal Women with Osteoporosis and Osteoarthritis
por: Lane, Nancy, et al.
Publicado: (2019)

Early Effects of Abaloparatide on Bone Formation and Resorption Indices in Postmenopausal Women With Osteoporosis
por: Dempster, David W, et al.
Publicado: (2021)

Abaloparatide in Postmenopausal Women With Osteoporosis and Type 2 Diabetes: A Post Hoc Analysis of the ACTIVE Study
por: Dhaliwal, Ruban, et al.
Publicado: (2020)

ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis
por: Bone, Henry G, et al.
Publicado: (2018)

Erratum for Abaloparatide in Postmenopausal Women With Osteoporosis and Type 2 Diabetes: A Post Hoc Analysis of the ACTIVE Study
por: Dhaliwal, Ruban, et al.
Publicado: (2020)

Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures
por: Austin, Matthew, et al.
Publicado: (2012)

Cardiovascular Safety of Abaloparatide in Postmenopausal Women With Osteoporosis: Analysis From the ACTIVE Phase 3 Trial
por: Cosman, Felicia, et al.
Publicado: (2020)

Predictors of Imminent Risk of Nonvertebral Fracture in Older, High‐Risk Women: The Framingham Osteoporosis Study
por: Hannan, Marian T, et al.
Publicado: (2019)

The Direct Assessment of Nonvertebral Fractures in Community Experience (DANCE) study: 2-year nonvertebral fragility fracture results
por: Silverman, S., et al.
Publicado: (2013)

Osteoporosis, vertebral fractures and metabolic syndrome in postmenopausal women
por: El Maghraoui, Abdellah, et al.
Publicado: (2014)

Is abaloparatide more efficacious on increasing bone mineral density than teriparatide for women with postmenopausal osteoporosis? An updated meta-analysis
por: Hong, Pan, et al.
Publicado: (2023)

Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis
por: Meunier, P. J., et al.
Publicado: (2009)

Abaloparatide followed by alendronate in women ≥80 years with osteoporosis: post hoc analysis of ACTIVExtend
por: Greenspan, Susan L., et al.
Publicado: (2020)

Phase 1b Evaluation of Abaloparatide Solid Microstructured Transdermal System (Abaloparatide-sMTS) in Postmenopausal Women with Low Bone Mineral Density
por: Miller, Paul D., et al.
Publicado: (2021)

SAT-519 Effect of Abaloparatide on Bone Mineral Density and Fracture Incidence in a Subset of Younger Postmenopausal Women with Osteoporosis at High Risk for Fracture Representative of Covered Commercial Insurance Enrollees
por: Saag, Kenneth, et al.
Publicado: (2019)

Relationship between Change in Bone Mineral Density of Lumbar Spine and Risk of New Vertebral and Nonvertebral Fractures: A Meta‐Analysis
por: Chen, Liang, et al.
Publicado: (2022)

Measurement of cortical porosity of the proximal femur improves identification of women with nonvertebral fragility fractures
por: Ahmed, L. A., et al.
Publicado: (2015)

Cost-effectiveness Analysis of Sequential Treatment of Abaloparatide Followed by Alendronate Versus Teriparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis in the United States
por: Le, Quang A., et al.
Publicado: (2018)

Increased cortical porosity and reduced cortical thickness of the proximal femur are associated with nonvertebral fracture independent of Fracture Risk Assessment Tool and Garvan estimates in postmenopausal women
por: Kral, Rita, et al.
Publicado: (2017)

European guidance for the diagnosis and management of osteoporosis in postmenopausal women
por: Kanis, J.A., et al.
Publicado: (2018)

Strontium ranelate reduces the risk of vertebral fracture in young postmenopausal women with severe osteoporosis
por: Roux, C, et al.
Publicado: (2008)

Relationship Between Bone Mineral Density T‐Score and Nonvertebral Fracture Risk Over 10 Years of Denosumab Treatment
por: Ferrari, S, et al.
Publicado: (2019)

Correction to: European guidance for the diagnosis and management of osteoporosis in postmenopausal women
por: Kanis, J.A., et al.
Publicado: (2020)

Cost-Effectiveness of Sequential Abaloparatide/Alendronate in Men at High Risk of Fractures in the United States
por: Hiligsmann, Mickaël, et al.
Publicado: (2023)

European guidance for the diagnosis and management of osteoporosis in postmenopausal women
por: Kanis, J. A., et al.
Publicado: (2012)

Thoracolumbar kyphosis in postmenopausal osteoporosis patients without vertebral compression fractures
por: Guo, Rui, et al.
Publicado: (2022)

European guidance for the diagnosis and management of osteoporosis in postmenopausal women
por: Kanis, J. A., et al.
Publicado: (2008)

European guidance for the diagnosis and management of osteoporosis in postmenopausal women
por: Kanis, J. A., et al.
Publicado: (2008)

Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years
por: Ferrari, S., et al.
Publicado: (2015)

Validation of an osteoporosis self-assessment tool to identify primary osteoporosis and new osteoporotic vertebral fractures in postmenopausal Chinese women in Beijing
por: Yang, Yong, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_dajeimu9tsecejc2m8rv2dgdpr